Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -
- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment -
- Plasma and CSF biomarkers support zervimesine’s impact on Alzheimer’s disease biology -

Read more at globenewswire.com